India’s leading integrated chemical manufacturer, Epigral Ltd, today announced its financial results for the quarter ended March 31, 2026.
The company reported its highest-ever quarterly revenue of ₹736 crore, registering a growth of 17% from ₹631 crore in Q4FY25. Profit After Tax (PAT) stood at ₹82 crore for the quarter, compared to ₹87 crore in the corresponding period last year. The Board has proposed a final dividend of ₹5 per equity share (50% of face value) for FY2026. On a sequential basis, Epigral witnessed strong recovery and growth momentum, driven by improved volumes and realizations. Revenue grew by 22% in Q4FY26 to ₹736 Cr as against ₹603 crore in Q3FY26, supported by higher plant utilization and normalized inventory costs. EBITDA margin improved to 23% from 17% in Q3FY26, reflecting operational efficiencies. PAT jumped by 109 % in Q4FY26 to ₹82 Cr as against ₹39 Cr in Q3FY26.
Commenting on the performance, Maulik Patel, Chairman and Managing Director – Epigral said:
“In Q4 FY26, we delivered record revenue of ₹736 crore, driven by a 15% sequential increase and 14% year-on-year growth in volumes. This performance reflects strong demand conditions and a full recovery post scheduled maintenance in Q3. Improved utilization levels and stabilization in raw material costs supported EBITDA margins of 23%.
While FY26 saw some impact due to an extended monsoon and planned maintenance in the first half, demand recovery began in November and strengthened through Q4. We expect this momentum to continue into FY27, subject to global macro conditions”.
